Table 1: Demographic and clinical characteristics of the study population (n=43).
| Parameter |
Value |
| Age, years |
49±4 |
| Weight, kg |
73.6±4.0 |
| Height, cm |
177±6 |
| BMI, kg/m2
|
23.5±1.5 |
| NYHA class |
2.3±0.4 |
| LVEF, % |
34±8 |
| BNP, pg/ml |
112±34 |
| Heart rate, min -1 |
87±12 |
| SBP, mmHg |
145±23 |
| DBP, mmHg |
87±14 |
| SaO2,% |
98.6±1.1 |
| PaCO2, mmHg |
35.8±1.5 |
| PaO2, mmHg |
86.8±4.7 |
| VC, % predicted |
97.7±3.3 |
| FVC, % predicted |
95.0±2.6 |
| FEV1, % predicted |
95.0±2.3 |
| FEV1/FVC, % predicted |
0.98±0.05 |
| Breathing rate, min-1
|
11.3±2.1 |
| Medical therapy |
| ACE-I/ARB, % |
98 |
| ß-blockers, % |
100 |
| Aldosterone antagonists, % |
88 |
| Loop diuretics, % |
35 |
| Thiazide diuretics, % |
40 |
| Statins, % |
79 |
BMI – body mass index, NYHA – New-York Heart Association, LVEF – left ventricle ejection fraction, BNP – brain natriuretic peptide, SBP – systolic blood pressure, DBP - diastolic blood pressure, SaO2 – oxygen saturation, PaCO2 - arterial carbon dioxide partial pressure, PaO2 - arterial oxygen partial pressure VC - vital capacity, FVC – forced vital capacity, FEV1 – forced expiratory volume in a first second, ACE-I/ARB - angiotensin-converting enzyme inhibitor/angiotensin receptor blocker